Strand Diagnostics’s management teams are comprised of industry-leading business executives and medical professionals with decades of experience in laboratory services. Meet our board members.
Peter M. Knapp, MD, FACS
Dr. Knapp is Co-Founder and Director of Strand Diagnostics LLC, and co-developer of the Know Error DNA Specimen Provenance Assignment (DSPA) test and kit used to improve diagnostic accuracy and patient safety in the evaluation of patient tissue specimens. Dr. Knapp is a practicing urologist involved in medical education, clinical research, product development, practice growth and clinical service line expansion for over 25 years. He holds multiple healthcare patents, has authored more than 30 articles and several book chapters, and served as principal investigator or sub-investigator on more than 50 clinical trials. Dr. Knapp is the past President of Urology of Indiana, a 35 physician urology group practice, and serves as Volunteer Clinical Associate Professor of Urology at Indiana University School of Medicine. He is Past President of the North Central Section of the American Urologic Association, Past President of the Large Urology Group Practice Association and remains active in the health policy and healthcare advocacy activities of both national organizations. Dr. Knapp has also served as consultant to other healthcare industry companies by providing strategic guidance on product development and application.
Dr. Knapp is a graduate of Indiana University and the Indiana University School of Medicine. He completed his general surgery internship and urology residency at the University of Michigan in Ann Arbor, Michigan. He is certified by the American Board of Urology and is a fellow of the American College of Surgeons.
Phillip Gordon is currently the Director of the CSS Institute of Advanced Health in Phoenix, Arizona. Mr. Gordon’s success story includes political and policy development in designing and implementing strategies to create new business opportunities, prevent problems or resolve conflicts facing clients. He was the Mayor of Phoenix from 2004 to 2011 and has an extensive list of community involvement. Mr. Gordon has a law degree from Arizona State University College of Law and his undergraduate work was in History and Government at the University of Arizona in Tucson, Arizona.
Theodore “Ted” Schenberg
Mr. Schenberg is a principal and co-founder of Caravel Ventures, a private equity group syndicating growth capital raises for lower middle market companies needing both financial and managerial support. Caravel’s current portfolio includes Strand Diagnostics (a CLIA-accredited forensic and medical DNA testing lab) for which Mr. Schenberg has been the CEO since 2007, and Animated Dynamics (engaged in the biodynamic imaging of cancer tissues) for which Mr. Schenberg is also CEO.
Mr. Schenberg has founded and/or acquired several companies in the life-science, chemical, aerospace, internet security, construction, and food processing industries. He has an extensive track-record of executive leadership as well as building value for stakeholders in his companies in partnership with his management teams. He has deep experience with start-ups, turnarounds, and merger/acquisition activities with a strong emphasis on commercialization activities. Three of the companies founded or purchased by Mr. Schenberg were subsequently sold to publicly-traded firms. He holds two patents and has taught courses on business and entrepreneurship at assorted venues including Indiana University Kelly School of Business from which he also holds a B.S. in Accounting and a Masters in Business Administration.
After three years in the audit department of KPMG Peat Marwick focusing on lower middle market clients, Travis Morgan embarked on a successful career as a private equity investor and entrepreneur. As Co-founder and Managing Director of Caravel Ventures, Travis has been directly responsible for 18 capital infusions into 12 different operating companies, serving as the full-time President or CFO of 7 of those portfolio companies. His credits include securing over $103 million in funded capital transactions, including three liquidity events with publicly traded firms. Mr. Morgan graduated at the age of 20 from the Indiana University Kelly School of Business with a Bachelor of Science in Accounting and Finance, and is a CPA (inactive) licensed in Indiana. He received an MBA with concentrations in entrepreneurship and international business from Babson. He is a certified Lean Six Sigma Greenbelt, and an alumnus of the Indianapolis Business Journal’s “Forty under 40” list, recognizing the state’s top business leaders under the age of forty (class of 2000).
Shahrooz Rabizadeh, Ph.D.
Mr. Shahrooz Rabizadeh, Ph.D. serves as Chief Scientific Officer at NantOmics, LLC and NantBioScience, Inc. Previously, Mr. Rabizadeh was the Director of Molecular Drug Discovery at Abraxis BioScience, Inc. and an Adjunct Assistant Professor of Bioengineering at the University of California, Los Angeles. Prior to Abraxis, he co-directed the Discovery Translation Unit at the Buck Institute, where he also served as an Assistant Research Professor. He received his PhD degree